Retina billing is in a category of its own. With the rising cost of medications and the widespread use of buy-and-bill drugs, the financial stakes for physicians continue to grow. When practices must supply costly injectable medications upfront, timely claim reimbursement becomes critical.
In retina billing, there are very few generic medications that are considered safe for intravitreal administration, and insurance companies often use multiple tactics to delay payment.
Successful retina billing requires a deeper level of strategy compared to many other specialties. As anti-VEGF medication use continues to rise due to increasing rates of diabetes and an aging population with age-related macular degeneration, practices must be proactive in protecting reimbursement and preventing denials.
Although insurance policies vary by carrier and state, the following are some of the most common factors contributing to delayed reimbursement and payment denials.
Prior Authorization Requirements and Benefit Verifications
Every insurance carrier has its own prior authorization policies and preferred drug lists. Many patients begin treatment with lower-cost medications such as Avastin, but for some patients it may not provide an adequate therapeutic response. As a result, patients are often transitioned to more expensive anti-VEGF medications relatively quickly.
It is essential to verify each patient’s insurance requirements for both prior authorization and buy-and-bill coverage before administering any injections. These are often separate processes. A medication may receive prior authorization approval while the patient still lacks coverage for physician-administered buy-and-bill drugs. Failing to verify both can result in costly reimbursement issues.
Clear and Concise Documentation
When denials occur, documentation becomes one of the most important tools in proving medical necessity. While documentation may not overturn every denial, it also plays a significant role in prior authorization approvals, appeals, and post-payment audits.
Every visit note should have a clearly documented treatment plan, including medication failures, response history, and the number of administrations for each medication. When this information is difficult to locate within the visit note, practices risk denied prior authorizations, payment retractions, and delays in patient treatment.
Coding to the Highest Level of Specificity
Diagnosis coding should always reflect the highest level of specificity. Missing laterality, unspecified disease states, and incomplete diagnosis documentation remain some of the leading causes of denials in retina billing.
All unspecified diagnoses should be reviewed and corrected before finalizing visit notes. Laterality modifiers should also be carefully verified for accuracy. Small coding errors can significantly impact reimbursement timelines and audit risk.
Staying Current With LCDs and FDA Guidelines
Not every cause of macular edema qualifies for anti-VEGF treatment coverage. The FDA approves these medications for specific conditions and clinical indications. Common qualifying diagnoses include:
- Diabetic retinopathy with macular edema
- Exudative age-related macular degeneration
- Retinopathy of prematurity
- Retinal vein occlusions with associated macular edema
In many cases, anti-VEGF therapy may not be approved if macular edema is not documented. Practices should routinely review Local Coverage Determinations (LCDs), pharmaceutical billing guidelines, and the most current FDA indications for each medication. For example, Eylea HD was recently approved for retinal vein occlusions when macular edema is present. Prior to this FDA update, Eylea HD would not have qualified for that diagnosis, while standard Eylea would have. Failing to stay current on these updates can result in denied claims and lost revenue.
While many additional factors influence retina reimbursement, these are among the most common causes of payment delays and reimbursement retractions. Practices should never assume that insurance policies are uniform, even within the same carrier. Performing due diligence before medication administration is essential.
Clear documentation is a goal every physician strives for, but increasing patient volumes and administrative burden often lead to preventable mistakes. Understanding the most common problem areas allows practices to identify risks early, improve reimbursement outcomes, and reduce treatment delays for patients.
